Company Snapshot
- Ticker
- PODD
- Name
- PODD
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 20593770883.110001
- Volume
- 697,949
- Avg Volume (3M)
- 646,009
PODD
PODD
Last update recent
291.51
-4.19
(-1.42%)
Market Cap
20593770883.110001
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 2521900000.000000
- EPS
- 3.50
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.0%
- Net Income
- 246200000.000000
- Net Margin
- 9.76%
- Payout Ratio
- 0.0%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 83.65
- Forward P/E
- None
- P/S
- 8.17
- P/B
- 14.88
- Beta
- None
- Debt / Equity
- 0.75
- Current Ratio
- 2.87
- Return on Equity
- 0.18%
- Return on Assets
- 0.08%
Technicals & Returns
- Distance vs 200 DMA
- -3.24%
- 200 DMA
- 301.26
- Distance vs 50 DMA
- -8.38%
- 50 DMA
- 318.18
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massa Read more
- Name
- PODD
- Industry
- Medical - Devices
- CEO
- Dr. James R. Hollingshead Ph.D.
- Employees
- 3,000
- IPO Date
- 2007-05-15
- Phone
- 978 600 7000
- Address
- None
- Website
- https://www.insulet.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Latest News
Curated headlines from premium sources.
4 Medical Device Stocks to Buy for Healthy Returns in 2026
ISRG, PODD, BSX and IDXX lead medtech innovation with AI, robotics and diagnostics for growth in 2026.
Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its …
Geneos Wealth Management Inc. Sells 3,253 Shares of Insulet Corporation $PODD
Geneos Wealth Management Inc. lowered its stake in shares of Insulet Corporation (NASDAQ: PODD) by 9.2% in the undefined quarter, according to the company in i…
Frontier Capital Management Co. LLC Buys 2,683 Shares of Insulet Corporation $PODD
Frontier Capital Management Co. LLC boosted its stake in Insulet Corporation (NASDAQ: PODD) by 3.0% in the undefined quarter, according to its most recent disc…
Here is Why Growth Investors Should Buy Insulet (PODD) Now
Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements
Insulet Stock rises as the FDA clears key Omnipod 5 upgrades that enhance glucose targets and automation for its tubeless diabetes platform.